News | April 13, 2008

Aortic Valve Implant Marks a First in North America

April 14 - Doctors implanted the ATS 3f Aortic Bioprosthesis, marking the first North American commercial implant after ATS Medical Inc. received Canadian regulatory approval for the device at the end of December, 2007.

The first implant was performed by Benoit de Varennes, M.D., MSc, FRSC, chairman, Division of Cardiac Surgery at McGill University in Montreal, Canada. The patient was a 76-year-old man with aortic valve stenosis. The valve replacement was successful and the patient has been discharged from the hospital in good condition.

The ATS 3f Aortic Bioprosthesis incorporates a design intended to preserve native aortic root geometry and function. Through this approach, the prosthesis is said to more closely mimics native valve function providing hemodynamic function that may contribute to improvements in key determinants of cardiovascular performance such as coronary blood flow and left ventricular mass regression. Data suggests that physiologic stresses, a detriment to bioprosthetic valve longevity, may be more efficiently distributed throughout the prosthetic's leaflets.

"The ATS 3F valve incorporates important characteristics of many other valves all in one product. The hemodynamic characteristics are very good and the valve offers the potential for longer durability. Previous stentless valve designs appeared to have good hemodynamic performance, but complex implantation techniques made many surgeons reticent to use them widely. The ATS 3F valve requires a very simple technique to implant which is easy to reproduce and should lead to more patients benefiting from its many performance attributes," said Dr. de Varennes.

For more information: www.atsmedical.com

Related Content

News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
News | Heart Valve Technology
February 28, 2022 - Foldax, Inc. has announced the presentation of results from the first animal study of its ...
Home February 28, 2022
Home
News | Heart Valve Technology
February 14, 2022 — SMT (Sahajanand Medical Technologies Limited) has announced the publication of Hydra Transcatheter ...
Home February 14, 2022
Home
News | Heart Valve Technology

December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for ...

Home December 13, 2021
Home
News | Heart Valve Technology

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

Home November 09, 2021
Home
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
Subscribe Now